Every 8-K that NAYA Biosciences, Inc. (NAYA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow NAYA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NAYA filings page.
INVO Fertility, Inc. filed an 8-K describing a change in its independent auditor and reiterating prior going concern language. On September 3, 2025, the company notified M&K CPAS, PLLC of its dismissal as independent registered public accounting firm, effective September 5, 2025, a decision approved by the board’s Audit Committee. M&K’s audit reports on the company’s 2023 and 2024 consolidated financial statements did not contain adverse or qualified opinions, but they did express substantial doubt about INVO Fertility’s ability to continue as a going concern. The company states there were no disagreements or reportable events with M&K. On September 5, 2025, the Audit Committee approved the engagement of WithumSmith+Brown, PC as the new independent registered public accounting firm for the year ending December 31, 2025, and INVO Fertility notes it had not previously consulted Withum on accounting or audit matters described in the 8-K.
INVO Fertility entered an Amendment and Exchange Agreement with Five Narrow Lane LP, replacing its existing convertible debenture with a Second Amended and Restated Senior Secured Convertible Debenture. The principal was set at $1,751,343.75, monthly redemption provisions were removed, and other mutually agreed changes were made.
In exchange, the parties reduced principal by $1,300,000 through issuance of 325 shares of Series C-2 Preferred (aggregate stated value $1,300,000) under a prior additional investment right. A Side Letter extended registration timing for resale of shares underlying the debenture, Series C-2 Preferred, and warrants: filing by August 29, 2025 and effectiveness by the earlier of September 30, 2025 (or October 31, 2025 if full review) or two business days after an SEC no-review notice. The debenture bears 7% interest, matures on February 11, 2026, converts at $1.4765 per share with a 9.99% beneficial ownership cap, and restricts prepayment without holder consent. If the company raises over $3,000,000 in non-public financings, one-third of proceeds may be applied to redemption at the holder’s option.
INVO Fertility, Inc. furnished a press release announcing its financial results for the quarter ended June 30, 2025. The company reported these results through a press release dated August 14, 2025, which is included as Exhibit 99.1. This information is being furnished under a current report and is expressly stated not to be deemed filed for purposes of certain liability provisions of the Securities Exchange Act of 1934 or incorporated into other securities law filings unless specifically referenced.